- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Phospho-NFATC2-pS330 Antibody Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP3429a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Phospho-NFATC2-pS330 Antibody Blocking Peptide - Product info | |
| Primary Accession | Q13469 |
| Other Accession | NP_036472 |
| Clone Names | 110162 |
| Calculated MW | 100146 Da |
Phospho-NFATC2-pS330 Antibody Blocking Peptide - Additional info | |
| Gene ID 4773 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP3429a was selected from the region of human Phospho-NFATC2-pS330. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
Phospho-NFATC2-pS330 Antibody Blocking Peptide - Protein Information | |
| Name NFATC2 | |
| Synonyms NFAT1, NFATP | |
| Function Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2, IL-3, IL-4, TNF-alpha or GM-CSF. Promotes invasive migration through the activation of GPC6 expression and WNT5A signaling pathway | |
| Cellular Location Cytoplasm. Nucleus. Note=Cytoplasmic for the phosphorylated form and nuclear after activation that is controlled by calcineurin-mediated dephosphorylation. Rapid nuclear exit of NFATC is thought to be one mechanism by which cells distinguish between sustained and transient calcium signals The subcellular localization of NFATC plays a key role in the regulation of gene transcription | |
| Tissue Location Expressed in thymus, spleen, heart, testis, brain, placenta, muscle and pancreas. Isoform 1 is highly expressed in the small intestine, heart, testis, prostate, thymus, placenta and thyroid. Isoform 3 is highly expressed in stomach, uterus, placenta, trachea and thyroid | |
Phospho-NFATC2-pS330 Antibody Blocking Peptide - Related products
AP3429a: Phospho-NFATC2-pS330 Antibody
AP3508a: Phospho-NFATC2-pS326 Antibody
AP7766a: NFATC2 Antibody (S330)
RI13570: NFATC2 predesign siRNA
BP3429a: Phospho-NFATC2-pS330 Antibody Blocking Peptide
BP3508a: Phospho-NFATC2-pS326 Antibody Blocking Peptide
Phospho-NFATC2-pS330 Antibody Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
NFATC2 is a member of the nuclear factor of activated T cells (NFAT) family. It is a DNA-binding protein with a REL-homology region (RHR) and an NFAT-homology region (NHR). This protein is present in the cytosol and only translocates to the nucleus upon T cell receptor (TCR) stimulation, where it becomes a member of the nuclear factors of activated T cells transcription complex. This complex plays a central role in inducing gene transcription during the immune response.
REFERENCES
Golks,A., EMBO J. 26 (20), 4368-4379 (2007)Dong,X., J. Biol. Chem. 282 (41), 30303-30310 (2007)Gibson,H.M., J. Immunol. 179 (6), 3831-3840 (2007)